Discovery of PG545: A highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis

Journal of Medicinal Chemistry

Volumn 55, Issue 8, 2012, Pages 3804-3813

  Ferro, Vito ^a,c   Liu, Ligong ^a,c   Johnstone, Ken D ^a,d   Wimmer, Norbert ^a,e   Karoli, Tomislav ^a,c   Handley, Paul ^a   Rowley, Jessica ^a   Dredge, Keith ^a   Li, Cai Ping ^a,f   Hammond, Edward ^a   Davis, Kat ^a   Sarimaa, Laura ^a,g   Harenberg, Job ^b   Bytheway, Ian ^a  

^a Progen Pharmaceuticals Limited   (Australia)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d National Food Technology Research Centre   (Botswana)

^e Alchemia Ltd   (Australia)

^f QLD Health Forensic and Scientific Services   (Australia)

^g GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA CHOLESTANYL 2,3,4,6 TETRA O SULFO ALPHA DEXTRO GLUCOPYRANOSYL (1-4) 2,3,6 TRI O SULFO ALPHA DEXTRO GLUCOPYRANOSYL (1-4) 2,3,6 TRI O SULPHO ALPHA DEXTRO GLUCOPYRANOSYL (1-4) 2,3,6 TRIO SULFO BETA DEXTRO GLUCOPYRANOSIDE, TRIDECASODIUM SALT; ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; HEPARAN SULFATE; HEPARIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RAT; TUMOR MODEL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GLUCURONIDASE; HEPARITIN SULFATE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SAPONINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860271832     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201708h     Document Type: Article

References (37)

1. Ferrara, N.; Kerbel, R. S. Angiogenesis as a therapeutic target Nature 2005, 438, 967-974 (Pubitemid 43093963)
2. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discovery 2007, 6, 273-286 (Pubitemid 46505878)
3. Herbst, R. S. Therapeutic options to target angiogenesis in human malignancies Expert Opin. Emerging Drugs 2006, 11, 635-650 (Pubitemid 44735590)
4. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 2008, 8, 592-603
5. Casanovas, O.; Hicklin, D. J.; Bergers, G.; Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 2005, 8, 299-309 (Pubitemid 41443415)
6. Paez-Ribes, M.; Allen, E.; Hudock, J.; Takeda, T.; Okuyama, H.; Vinals, F.; Inoue, M.; Bergers, G.; Hanahan, D.; Casanovas, O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 2009, 15, 220-231
7. Ebos, J. M.; Lee, C. R.; Cruz-Munoz, W.; Bjarnason, G. A.; Christensen, J. G.; Kerbel, R. S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 2009, 15, 232-239
8. Loges, S.; Mazzone, M.; Hohensinner, P.; Carmeliet, P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 2009, 15, 167-170
9. Force, T.; Kolaja, K. L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat. Rev. Drug Discovery 2011, 10, 111-126
10. Casu, B.; Vlodavsky, I.; Sanderson, R. D. Non-anticoagulant heparins and inhibition of cancer Pathophysiol. Haemostasis Thromb. 2008, 36, 195-203
11. Hammond, E.; Bytheway, I.; Ferro, V. Heparanase as a Target for Anticancer Therapeutics: New Developments and Future Prospects. In New Developments in Therapeutic Glycomics; Delehedde, M.; Lortat-Jacob, H., Eds.; Research Signpost: Trivandrum, India, 2006; pp 251-282.
12. McKenzie, E. A. Heparanase: a target for drug discovery in cancer and inflammation Br. J. Pharmacol. 2007, 151, 1-14 (Pubitemid 46675998)
13. Parish, C. R.; Freeman, C.; Brown, K. J.; Francis, D. J.; Cowden, W. B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity Cancer Res. 1999, 59, 3433-3441 (Pubitemid 29334505)
14. Liu, C. J.; Lee, P. H.; Lin, D. Y.; Wu, C. C.; Jeng, L. B.; Lin, P. W.; Mok, K. T.; Lee, W. C.; Yeh, H. Z.; Ho, M. C.; Yang, S. S.; Lee, C. C.; Yu, M. C.; Hu, R. H.; Peng, C. Y.; Lai, K. L.; Chang, S. S.; Chen, P. J. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage J. Hepatol. 2009, 50, 958-968
15. Recent review: Kudchadkar, R.; Gonzalez, R.; Lewis, K. D. PI-88: a novel inhibitor of angiogenesis Expert Opin. Invest. Drugs 2008, 17, 1769-1776
16. Johnstone, K. D.; Karoli, T.; Liu, L.; Dredge, K.; Copeman, E.; Li, C. P.; Davis, K.; Hammond, E.; Bytheway, I.; Kostewicz, E.; Chiu, F. C.; Shackleford, D. M.; Charman, S. A.; Charman, W. N.; Harenberg, J.; Gonda, T. J.; Ferro, V. Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth J. Med. Chem. 2010, 53, 1686-1699
17. Wall, D.; Douglas, S.; Ferro, V.; Cowden, W.; Parish, C. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides Thromb. Res. 2001, 103, 325-335 (Pubitemid 32787023)
18. Karoli, T.; Liu, L.; Fairweather, J. K.; Hammond, E.; Li, C. P.; Cochran, S.; Bergefall, K.; Trybala, E.; Addison, R. S.; Ferro, V. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88) J. Med. Chem. 2005, 48, 8229-8236 (Pubitemid 43032531)
19. Ferro, V.; Dredge, K.; Liu, L.; Hammond, E.; Bytheway, I.; Li, C.; Johnstone, K.; Karoli, T.; Davis, K.; Copeman, E.; Gautam, A. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis Semin. Thromb. Hemostasis 2007, 33, 557-568
20. Yu, G.; Gunay, N. S.; Linhardt, R. J.; Toida, T.; Fareed, J.; Hoppensteadt, D. A.; Shadid, H.; Ferro, V.; Li, C.; Fewings, K.; Palermo, M. C.; Podger, D. Preparation and anticoagulant activity of the phosphosulfomannan PI-88 Eur. J. Med. Chem. 2002, 37, 783-791 (Pubitemid 35350842)
21. Cochran, S.; Li, C.; Fairweather, J. K.; Kett, W. C.; Coombe, D. R.; Ferro, V. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance J. Med. Chem. 2003, 46, 4601-4608 (Pubitemid 37238760)
22. Cochran, S.; Li, C. P.; Ferro, V. A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins Glycoconjugate J. 2009, 26, 577-587
23. Hammond, E.; Li, C. P.; Ferro, V. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening Anal. Biochem. 2010, 396, 112-116
24. Dredge, K.; Hammond, E.; Davis, K.; Li, C. P.; Liu, L.; Johnstone, K.; Handley, P.; Wimmer, N.; Gonda, T. J.; Gautam, A.; Ferro, V.; Bytheway, I. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy Invest. New Drugs 2010, 28, 276-283
25. Fairweather, J. K.; Hammond, E.; Johnstone, K. D.; Ferro, V. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88 Bioorg. Med. Chem. 2008, 16, 699-709 (Pubitemid 351187755)
26. Tornøe, C. W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides J. Org. Chem. 2002, 67, 3057-3064 (Pubitemid 34457265)
27. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew. Chem., Int. Ed. 2002, 41, 2596-2599 (Pubitemid 34803480)
28. Liu, L.; Johnstone, K.; Fairweather, J. K.; Dredge, K.; Ferro, V. An improved synthetic route to the potent angiogenesis inhibitor benzyl manα(1→3)-manα(1→3)-manα(1→3) -manα(1→2)-man hexadecasulfate Aust. J. Chem. 2009, 62, 546-552
29. Imberty, A.; Lortat-Jacob, H.; Pérez, S. Structural view of glycosaminoglycan-protein interactions Carbohydr. Res. 2007, 342, 430-439 (Pubitemid 46161422)
30. Coombe, D. R.; Kett, W. C. Heparan sulfate-protein interactions: therapeutic potential through structure-function insights Cell. Mol. Life Sci. 2005, 62, 410-424 (Pubitemid 40385034)
31. Raman, R.; Sasisekharan, V.; Sasisekharan, R. Structural insights into biological roles of protein-glycosaminoglycan interactions Chem. Biol. 2005, 12, 267-277 (Pubitemid 40406273)
32. Capila, I.; Linhardt, R. J. Heparin-protein interactions Angew. Chem., Int. Ed. 2002, 41, 391-412
33. Auerbach, R.; Lewis, R.; Shinners, B.; Kubai, L.; Akhtar, N. Angiogenesis assays: a critical overview Clin. Chem. 2003, 49, 32-40 (Pubitemid 36078551)
34. Dredge, K.; Hammond, E.; Handley, P.; Gonda, T. J.; Smith, M. T.; Vincent, C.; Brandt, R.; Ferro, V.; Bytheway, I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models Br. J. Cancer 2011, 104, 635-642
35. Narumi, A.; Miura, Y.; Otsuka, I.; Yamane, S.; Kitajyo, Y.; Satoh, T.; Hirao, A.; Kaneko, N.; Kaga, H.; Kakuchi, T. End-functionalization of polystyrene by malto-oligosaccharide generating aggregation-tunable polymeric reverse micelle J. Polym. Sci., Part A: Polym. Chem 2006, 44, 4864-4879 (Pubitemid 44328038)
36. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
37. Min, J. K.; Han, K. Y.; Kim, E. C.; Kim, Y. M.; Lee, S. W.; Kim, O. H.; Kim, K. W.; Gho, Y. S.; Kwon, Y. G. Capsaicin inhibits in vitro and in vivo angiogenesis Cancer Res. 2004, 64, 644-651 (Pubitemid 38120905)